Area of research
Oncology · Surgery
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Cholangiocarcinoma and Gallbladder Cancer Studies, Hepatocellular Carcinoma Treatment and Prognosis, and Neuroendocrine Tumor Research Advances.
Phase 1 trial of HR070803 (an Irinotecan liposome) in combination with 5-fluorouracil, leucovorin, and oxaliplatin for untreated advanced or metastatic pancreatic ductal adenocarcinoma
International consensus guidelines on robotic pancreatic surgery in 2023
The effects of CYP2B6 inactivators on the metabolism of ciprofol
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
International experts consensus guidelines on robotic liver resection in 2023
A radiomics-based interpretable model to predict the pathological grade of pancreatic neuroendocrine tumors
Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.
Consensus of clinical diagnosis and treatment for non-functional pancreatic neuroendocrine neoplasms with diameter <2 cm
YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation
Robotic versus Open Pancreatoduodenectomy for Pancreatic and Periampullary Tumors (PORTAL): a study protocol for a multicenter phase III non-inferiority randomized controlled trial
Guidelines for the diagnosis and treatment of acute pancreatitis in China (2021)
Guidelines for the diagnosis and treatment of pancreatic cancer in China (2021)
Development and Validation of a New Nomogram for Predicting Clinically Relevant Postoperative Pancreatic Fistula After Pancreatoduodenectomy
MFAP5 facilitates the aggressiveness of intrahepatic Cholangiocarcinoma by activating the Notch1 signaling pathway
EYA4 inhibits hepatocellular carcinoma by repressing MYCBP by dephosphorylating β‐catenin at Ser552
EYA4 inhibits hepatocellular carcinoma growth and invasion by suppressing NF‐κB‐dependent RAP1 transactivation
Surgery management for sporadic small (≤2 cm), non-functioning pancreatic neuroendocrine tumors: A consensus statement by the Chinese Study Group for Neuroendocrine Tumors (CSNET)
Salivary microRNAs Show Potential as a Noninvasive Biomarker for Detecting Resectable Pancreatic Cancer